PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.1806
https://www.valueinhealthjournal.com/article/S1098-3015(19)34184-1/fulltext
Section Title :
Section Order :
11569
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34184-1&doi=10.1016/j.jval.2019.09.1806